期刊文献+

siRNA沉默SOCS1表达增强IFN-α2a-NGR的抗肿瘤效应 被引量:5

SOCS1 knockdown sensitize anti-tumor activity of IFN-α2a-NGR
下载PDF
导出
摘要 目的:研究肿瘤血管导向性干扰素IFN-α2a-NGR抗肿瘤效应的分子机制,发现影响干扰素敏感性的关键信号分子,提高耐药肿瘤细胞敏感性。方法:培养IFNAR高表达细胞株A549、IFNAR低表达细胞株MKN-45,通过MTT检测IFN-α2a-NGR的抗细胞增殖活性,流式细胞术(FCM)、Western blot检测IFN-α2a-NGR处理前后STAT1、p-STAT1、p53、OAS与SOCS1的表达变化,合成siRNA靶向干涉SOCS1。结果:IFN-α2a-NGR刺激后,A549中,p-STAT1、p53、OAS与SOCS1表达上调;MKN-45中P53、OAS无显著变化,SOCS1显著上调。靶向干涉SOCS1后,MKN-45对IFN-α2a-NGR的敏感性增加[抑制率从(14.69±1.05)%提高到(36.97±2.05)%]。结论:IFN-α2a-NGR与IFN-α2a在细胞和分子水平的效应基本一致,p-STAT1、p53与SOCS1可影响细胞对干扰素的敏感性,通过siRNA沉默技术可提高耐药细胞株敏感性,为IFN-α2a-NGR的进一步研发奠定了基础。 AIM:Search for key molecules to influence the tumor-targeted IFN-α2a-NGR anti-tumor sensitivity through signaling pathway study.Try to enhance the antitumor efficacy of IFN-α2a-NGR.METHODS:MTT method was used to determine the growth inhibitory effects of IFN-α2a-NGR on A549 and MKN-45 cells;Flow cytometry and Western blot were employed to detect the expression of STAT1,p-STAT1,p53,OAS and SOCS1;SOCS1 gene knock down was carried out by synthesized siRNA.RESULTS:When stimulated with IFN-α2a-NGR,the increased expression of STAT1,p-STAT1,p53,OAS and SOCS1 were observed in A549 cells,but only SOCS1 was notably increased in MKN-45 cells.The proliferation inhibition ability of MKN-45 to IFN-α2a-NGR was promoted by SOCS1 knocking down.(the inhibition rate was enhanced from 14.69%±1.05% to 36.97%±2.05%).CONCLUSION:This study has further demonstrated that there were no differences on antitumor effects between IFN-α2a-NGR and IFN-α2a on cell or molecular level.Besides interferon-α receptor (IFNAR) which has been demonstrated before,p-STAT1,p53 and SOCS1 were important determinants of tumor resistance to IFNs therapy.The antitumor efficacy of IFN-α2a-NGR can be enhanced by RNA interference.These results might be helpful for the further development of IFN-α2a-NGR.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2010年第5期412-415,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金面上项目(30572210) 国家高技术研究发展计划(863)资助项目(2007AA02204) 陕西省科技攻关项目(2008K09-09) 陕西省自然科学基金资助(2009JM4005)
关键词 干扰素 IFN-α2a-NGR 肿瘤 信号转导 interferon IFN-α2a-NGR tumor signal transduction
  • 相关文献

参考文献11

二级参考文献47

  • 1杜平.医用干扰素[M].北京:解放军出版社,1984.231-235.
  • 2Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails[J]. Cell Death Differ, 2006, 13(6) : 1017 -1026.
  • 3Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53 [J]. Curt Opin On, col, 2002, 14(1): 86 -91.
  • 4van der Burg SH, Menon AG, Redeker A, et al. Induction of p53- specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine[ JJ. Clin Cancer Res, 2002, 8(5) : 1019 -1027.
  • 5Prives C, Hall PA. The p53 pathway[J]. JPathol, 1999, 187(1): 112 -116.
  • 6O'Leary KA, Mendrysa SM, Vaccaro A, et al. MDM2 regulates P53 independently of p19 (ARF) in homeostatic tissues[ J]. Mol Cell Biol, 2004, 24(1): 186-191.
  • 7Kannan K, Amariglio N, Rechavi G, et al. DNA microarrays identification of primary and secondary target genes regulated by p53 [ J ]. Oncogene, 2001, 20(18) : 2225 -2234.
  • 8Vousden KH. p53 in health and disease[J]. Nat Rev Mol Cell Biol, 2007, 8(4): 275-283.
  • 9Bensaad K, Vousden KH. Savior and slayer: the two faces of p53 [J]. Nat Med, 2005, 11(12) : 1278 -1279.
  • 10Bui T, Thompson CB. Cancer's sweet tooth[J]. Cancer Cell, 2006, 9(6) : 419 -420.

共引文献24

同被引文献98

  • 1刘原照.α-干扰素在肿瘤治疗中的应用[J].中国处方药,2004,3(7):36-38. 被引量:5
  • 2胡礼仪,周新,张有顺,戴宗晴,黄玲,王菊.载体介导的RNA干扰技术抑制肝癌耐药细胞MDR1表达的研究[J].肿瘤防治杂志,2004,11(11):1158-1162. 被引量:8
  • 3秦维超,张有顺,周新,胡礼仪,黄玲.抑制MDR1基因表达shRNA RNAi系统的构建[J].山东医药,2005,45(13):19-20. 被引量:4
  • 4赵琪,黄学文,朱海林.天然型EGFP在无细胞翻译系统中的可溶表达[J].江苏大学学报(医学版),2007,17(3):225-227. 被引量:1
  • 5Oostendorp M,Douma K,Hackeng TM,et al.Quantitative molecu-lar magnetic resonance imaging of tumor angiogenesis using cNGR-la-beled paramagnetic quantum dots[J].Cancer Res,2008,68(18):7676-7683.
  • 6Corti A,Curnis F.Isoaspartate-dependent molecular switches for in-tegrin-ligand recognition[J].J Cell Sci,2011,124(Pt 4):515-522.
  • 7Zhao BJ,Ke XY,Huang Y,et al.The antiangiogenic efficacy ofNGR-modified PEG-DSPE micelles containing paclitaxel(NGR-M-PTX)for the treatment of glioma in rats[J].J Drug Target,2011,19(5):382-390.
  • 8Xu J,Maurer LM,Hoffmann BR,et al.iso-DGR sequences do notmediate binding of fibronectin N-terminal modules to adherent fi-bronectin-null fibroblasts[J].J Biol Chem,2010,285(12):8563-8571.
  • 9Curnis F,Cattaneo A,Longhi R,et al.Critical role of flanking resi-dues in NGR-to-isoDGR transition and CD13/integrin receptor switc-hing[J].J Biol Chem,2010,285(12):9114-9123.
  • 10Ndinguri MW,Solipuram R,Gambrell RP,et al.Peptide targeting ofplatinum anti-cancer drugs[J].Bioconjug Chem,2009,20(10):1869-1878.

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部